Stock Analysis
Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis
Vertex Pharmaceuticals Incorporated (VRTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Vertex Pharmaceuticals Incorporated (VRTX) currently has an AIQ Score of 63/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Value is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
VRTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $524.52 |
| AIQ Score | 63/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $139B |
| P/E Ratio (TTM) | 31.62 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $4.33 |
| Revenue (quarter ended 2026-06-30) | $3.33B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.31 |
| Volume | 1.45M |
| 52-week range | $403.16-$560.25 |
| RSI 14 | 58.97 |
| 50-Day SMA | $522.37 |
| 200-Day SMA | $476.84 |
| Analyst Price Target | $562.71 |
| Next Earnings | Nov 2, 2026 |
VRTXVertex Pharmaceuticals Incorporated
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum76
- Value32
- Quality82
- Risk resilience63
- Sentiment—
VRTX Stock Analysis Summary
Vertex Pharmaceuticals Incorporated (VRTX) currently has an AIQ Score of 63/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Value is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, VRTX has AIQ Score of 63/100 with Quality base of 82/100 and fading Value at 32/100. Wait for component alignment before adding exposure.
Quality (82/100) leads while Value (32/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.92% stock move · VRTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is VRTX Bullish or Bearish Right Now?
VRTX currently has a neutral overall setup. Quality is the strongest factor at 82/100, while Value is weakest at 32/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 82/100.
- - Momentum is constructive at 76/100.
- - Risk Resilience is supportive at 63/100.
- - Price is +0.41% above its 50-day SMA.
- - Analyst target implies +7.28% upside from the latest quote.
- - Value is the current constraint at 32/100.
Current Consensus
VRTX's Technical Analysis Consensus is currently Buy, with 31 buy, 5 neutral, and 9 sell votes. VRTX's 14-day RSI is 58.97, which places the stock in a constructive momentum range. VRTX's beta is 0.31, indicating lower market sensitivity than the broad market.
What Changed in VRTX?
The largest recent change in VRTX is Momentum moving up by 46.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the VRTX Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
VRTX Decision Framework
Public evidence layers, setup checks, and risk context for Vertex Pharmaceuticals Incorporated.
Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis
Vertex Pharmaceuticals Incorporated has an AIQ Score of 63/100 in a Neutral regime. Quality is strongest at 82/100. Beta is 0.32, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | VRTX is in a Neutral AIQ regime with score 63/100. |
| Signal Conflict | The primary conflict is that quality leads at 82/100 while value lags at 32/100. |
| Factor Evidence | Momentum 76/100 · Value 32/100 · Quality 82/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 82/100.
Momentum is 76/100 and RSI (14) is 59.0.
VRTX is in a Neutral regime at 63/100.
Risk factor is 63/100 with beta 0.32 and annual volatility 28.99%.
Current conflict: quality leads at 82/100 while value lags at 32/100.
VRTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
VRTX Fundamentals
VRTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
VRTX Technical Analysis
VRTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
VRTX Stock Catalysts
Track VRTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
VRTX Dividend Analysis
VRTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
VRTX Financial Data
VRTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
VRTX Risk Analysis
VRTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
VRTX Stock News
VRTX stock news, market tone, recent headlines, and catalyst context.
VRTX vs Large Cap Pharma Peers
Current peer cohort: VRTX · ABBV · AMGN · AZN · BHC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| VRTX Current stock | 63/100 | 32/100 | 76/100 | 63/100 | 0.79 | 28.99% | Current |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | VRTX vs ABBV |
| AMGN Amgen | 63/100 | 44/100 | 87/100 | 47/100 | 1.26 | 29.59% | VRTX vs AMGN |
| AZN AstraZeneca | 63/100 | 53/100 | 74/100 | 47/100 | 0.01 | 27.21% | VRTX vs AZN |
| BHC Bausch Health | 77/100 | 75/100 | 79/100 | 34/100 | 0.24 | 56.33% | VRTX vs BHC |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 22, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching VRTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for VRTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
VRTX Stock FAQ
What is VRTX stock price today?
Vertex Pharmaceuticals Incorporated's current stock price is $524.52. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is VRTX bullish or bearish right now?
VRTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is VRTX's market cap?
VRTX's market cap is $139B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is VRTX's current P/E ratio?
VRTX's current P/E ratio is 31.62 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is VRTX's RSI?
VRTX's 14-day RSI is 58.97 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is VRTX above its 50-day and 200-day moving averages?
VRTX is 0.41% from its 50-day SMA and 10.00% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is VRTX's next earnings date?
VRTX's next earnings date is currently listed as Nov 2, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does VRTX pay a dividend?
VRTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.